{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:21:27Z","timestamp":1778858487870,"version":"3.51.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Science and Technology Department of Guizhou Province","award":["(2016) 7399)"],"award-info":[{"award-number":["(2016) 7399)"]}]},{"name":"the Foundation for Innovation and Talent Team of the Higher Education of Guizhou Province","award":["2015 (51)"],"award-info":[{"award-number":["2015 (51)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study evaluated the efficacy and safety of docetaxel combined with lobaplatin, relative to docetaxel combined with gemcitabine, for treating patients with recurrent metastatic breast cancer (rMBC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients with rMBC received \u22652 cycles (21 days each) of either docetaxel and lobaplatin (DL; <jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a21), or docetaxel and gemcitabine (DG; <jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a22). On day 1 of each cycle, all patients were given 75\u200amg\/m<jats:sup>2<\/jats:sup> intravenous docetaxel. Patients in DL and DG were also given, respectively, 35\u200amg\/m<jats:sup>2<\/jats:sup> intravenous lobaplatin (day 2) or 1000\u200amg\/m<jats:sup>2<\/jats:sup> intravenous gemcitabine (days 1, 8).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Five (11.6%) and 16 (37.2%) patients achieved complete remission and partial response, respectively; rates of response and disease control were 48.8%. The response rates of the groups were comparable (47.6%, 50.0%). The median survival times after relapse and metastasis of the DL group (18 months) were significantly less than that of the DG group (25 months). Median progression-free survivals after relapse and metastasis were similar (12 cf. 14 months). The main toxic side reaction was grade 2, with no treatment-related deaths. Rates of the following were comparable between DG and DL: grade 3 or 4 white blood cells (23.8%, 31.8%) and digestive tract toxicity (4.8%, 4.5%); neutropenia (28.6%, 22.7%); anemia (4.8%, nil); and thrombocytopenia (19.0%, 13.6%). Other toxicities included hepatic toxicity, myalgia, infection, and fatigue.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Both the DL and DG regimens were associated with encouraging benefits, while treatment-related toxicity was manageable. Therefore, these regimens are effective options for treatment of rMBC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>This clinical trial study was approved by the Ethics Committee of Guizhou Cancer Hospital, and has been registered in the China Clinical Trial Center (December 8, 2014, No. ChiCTR-IPR-14005633).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000018513","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T20:38:40Z","timestamp":1577392720000},"page":"e18513","source":"Crossref","is-referenced-by-count":8,"title":["Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer"],"prefix":"10.1097","volume":"98","author":[{"given":"Fenghu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Guiyang Maternal and Child Health-Care Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyuan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiehui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heran","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiqin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Breast and Gynecologic Oncology, Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Breast and Gynecologic Oncology, Guizhou Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengxiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Guizhou Provincial Key Laboratory of Pathogenesis and Drug Research on Common Chronic Diseases; Guizhou Province Key Laboratory for Regenerative Medicine; Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,12]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00280-012-1901-3","article-title":"A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer","volume":"70","author":"Karachaliou","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000447549","article-title":"Systemic therapy of advanced\/metastatic breast cancer - current evidence and future concepts","volume":"11","author":"Liedtke","year":"2016","journal-title":"Breast Care (Basel)"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"Barrett-Lee","year":"2009","journal-title":"Ann Oncol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3892\/ol.2015.4030","article-title":"MicroRNA-205 increases the sensitivity of docetaxel in breast cancer","volume":"11","author":"Cai","year":"2016","journal-title":"Oncol Lett"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clbc.2016.05.006","article-title":"Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a Sarah Cannon Research Institute phase II trial","volume":"16","author":"Yardley","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13058-018-1014-y","article-title":"A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer","volume":"20","author":"Diamond","year":"2018","journal-title":"Breast Cancer Res"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4161\/15384047.2014.986973","article-title":"A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2012.46.2408","article-title":"Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer","volume":"31","author":"Baselga","year":"2013","journal-title":"J Clin Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10637-015-0281-z","article-title":"Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer","volume":"33","author":"van der Noll","year":"2015","journal-title":"Invest New Drugs"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000445936","article-title":"GEMOX: an active regimen for the treatment of luminal and human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"62","author":"Rizzi","year":"2017","journal-title":"Chemotherapy"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.clbc.2016.05.002","article-title":"Vinorelbine with capecitabine, an evergreen doublet for advanced breast cancer: a systematic literature review and pooled-analysis of phase II-III studies","volume":"16","author":"Petrelli","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nature15260","article-title":"Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells","volume":"526","author":"Lawson","year":"2015","journal-title":"Nature"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.canep.2015.09.010","article-title":"What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study","volume":"39","author":"Bakker","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.breast.2016.06.024","article-title":"Over-treatment in metastatic breast cancer","volume":"31","author":"Senkus","year":"2017","journal-title":"Breast"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.18.00242","article-title":"National cancer institute breast cancer steering committee working group report on meaningful and appropriate end points for clinical trials in metastatic breast cancer","author":"Seidman","year":"2018","journal-title":"J Clin Oncol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.breast.2013.03.006","article-title":"International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer","volume":"22","author":"Lin","year":"2013","journal-title":"Breast"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clbc.2015.10.005","article-title":"A Phase II randomized study of lapatinib combined with capecitabine, vinorelbine, or gemcitabine in patients with HER2-positive metastatic breast cancer with progression after a Taxane (Latin American Cooperative Oncology Group 0801 Study)","volume":"16","author":"G\u00f3mez","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ejca.2015.01.059","article-title":"Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"51","author":"Lorenzen","year":"2015","journal-title":"Eur J Cancer"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/07357907.2012.657812","article-title":"Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer","volume":"30","author":"Garcia","year":"2012","journal-title":"Cancer Invest"},{"key":"R21-20230915","first-page":"293","article-title":"Taxane-containing regimens for metastatic breast cancer","volume":"3","author":"Ghersi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3892\/ol.2014.2675","article-title":"A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy","volume":"9","author":"Peng","year":"2015","journal-title":"Oncol Lett"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.2147\/OTT.S108032","article-title":"Lobaplatin for the treatment of SK-MES-1 lung squamous cell line in vitro and in vivo","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/CAD.0b013e32834fb8ce","article-title":"Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro","volume":"23","author":"Engel","year":"2012","journal-title":"Anticancer Drugs"},{"key":"R25-20230915","first-page":"1090","article-title":"Randomized clinical study of short term efficacy and safety of paclitaxel combined with lobaplatin compared to paclitaxel combine with cisplatin in chemoradiotherapy of locally advanced cervical cancer","volume":"23","author":"Feng-hu","year":"2016","journal-title":"Chin J Cancer Prev Treat"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/imj.12773","article-title":"Comparison of efficacy and toxicity profiles between paclitaxel\/lobapoatin- and cisplatin\/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer","volume":"45","author":"Yang","year":"2015","journal-title":"Intern Med J"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.biopha.2014.12.011","article-title":"Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro","volume":"69","author":"Yang","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1634\/theoncologist.2013-0428","article-title":"A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer","volume":"19","author":"Seidman","year":"2014","journal-title":"Oncologist"},{"key":"R29-20230915","first-page":"223","article-title":"Chinese guideline for advanced breast cancer 2015 (CABC 2015)","volume":"13","year":"2015","journal-title":"Oncol Prog"},{"key":"R30-20230915","first-page":"2048","article-title":"Clinical observation of iobaplatin plus vinorelbine in treating 46 advanced breast cancer patients","volume":"20","author":"Yang","year":"2012","journal-title":"Modem Oncol"},{"key":"R31-20230915","first-page":"1044","article-title":"Effect of gemcitabine combined with docetaxel in th e treatment of advanced breast cancer: report of 48 cases","volume":"23","author":"Chun-Mei","year":"2016","journal-title":"Chin J Bases Clin Gen Surg"},{"key":"R32-20230915","first-page":"634","article-title":"Clinical effect of docetaxel combined with gemcitabine for patients with recurrent or metastatic breast cancer and its prognostic factors","volume":"40","author":"Zhang","year":"2013","journal-title":"J Int Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:16:06Z","timestamp":1694812566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"journal-issue":{"issue":"52","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018513","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}